Long term cost-effectiveness of low molecular weight heparin versus unfractionated heparin for the prophylaxis of venous thromboembolism in elective hip replacement

被引:0
作者
Marchetti, M [1 ]
Liberato, NL [1 ]
Ruperto, N [1 ]
Barosi, G [1 ]
机构
[1] Policlin San Matteo, IRCCS, Lab Informat Med, I-27100 Pavia, Italy
关键词
decision trees; decision support techniques; cost benefit analysis; heparin; low molecular weight therapeutic use; heparin economics; arthroplasty; replacement; hip adverse effects; thrombosis prevention and control;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Objective. Either low molecular weight heparin (LMWH) or unfractionated heparin (UH) may be used for the prophylaxis of post-operative venous thromboembolic disease (VTD) in elective hip replacement. This study was aimed at assessing the cost-effectiveness of LMWH over UH from the society perspective, which considers all the outcomes occurring in the lifelong time horizon. Design and Methods. A decision tree modeled the clinical outcomes and resources used in consequence of restricted (2 weeks) and extended (4 weeks) prophylaxis of VTD with LMWH or UH. Results. In the studied population, that of 67 year-old patients, restricted prophylaxis with LMWH saved 25 quality-adjusted days and $75 over UH. Extended prophylaxis provided a small additional benefit with additional cost savings. The incremental outcomes of the model proved independent of most parameters. Interpretation and Conclusions. We conclude that LMWH has considerable advantages over UH in the prophylaxis of VTD following elective hip replacement, and should be recommended in clinical practice. (C)1999, Ferrata Storti Foundation.
引用
收藏
页码:730 / 737
页数:8
相关论文
共 48 条
[41]   RESULTS OF THE 7-YEAR PROSPECTIVE-STUDY OF STROKE PATIENTS [J].
SCMIDT, EV ;
SMIRNOV, VE ;
RYABOVA, VS .
STROKE, 1988, 19 (08) :942-949
[42]  
Siragusa S, 1997, Minerva Cardioangiol, V45, P57
[43]  
UNWIN AJ, 1995, ANN ROY COLL SURG, V77, P351
[44]   OUTCOME ANALYSIS OF PATIENTS WITH NORMAL COMPRESSION US EXAMINATIONS [J].
VACCARO, JP ;
CRONAN, JJ ;
DORFMAN, GS .
RADIOLOGY, 1990, 175 (03) :645-649
[45]   ACCURACY OF CLINICAL-ASSESSMENT OF DEEP-VEIN THROMBOSIS [J].
WELLS, PS ;
HIRSH, J ;
ANDERSON, DR ;
LENSING, AWA ;
FOSTER, G ;
KEARON, C ;
WEITZ, J ;
DOVIDIO, R ;
COGO, A ;
PRANDONI, P ;
GIROLAMI, A ;
GINSBERG, JS .
LANCET, 1995, 345 (8961) :1326-1330
[46]   Length of hospital stay for treatment of deep venous thrombosis and the incidence of recurrent thromboembolism [J].
White, RH ;
Zhou, H ;
Romano, PS .
ARCHIVES OF INTERNAL MEDICINE, 1998, 158 (09) :1005-1010
[47]   COST-EFFECTIVENESS OF INTERFERON-ALPHA-2B TREATMENT FOR HEPATITIS-BE ANTIGEN-POSITIVE CHRONIC HEPATITIS-B [J].
WONG, JB ;
KOFF, RS ;
TINE, F ;
PAUKER, SG .
ANNALS OF INTERNAL MEDICINE, 1995, 122 (09) :664-675
[48]  
1998, DRUG THER B, V36, P25